

**Cc:** Rick Jaffe

**Subject:** RE: Your response to USA TODAY coverage

Dear Mrs. Poblete,

We made some amendments to the revised Letter to the Editor and you will find them below. There are 278 words in our amended letter, which is even less words than what you had. Please let me know if this is sufficient.

USA TODAY's recent articles about me and the clinical trials at the Burzynski Clinic contain misinformation and biased opinions on every point. I cannot rebut each point in this limited response. However the two articles omit the most important facts of our work and the results we have achieved. In our clinical trials, we treated some of the worst types of brain tumors which often have a life expectancy of less than one year. Our trials demonstrated a 19% long term survival rate and median survival rates far in excess of what conventional treatment offers this patient population.

Regrettably, the treatment doesn't help everyone. Frankly, at this stage in our research, there are many unanswered questions as to why this is. But there is no fair or legitimate question that there are numerous patients (77 to be exact) who had properly diagnosed incurable and terminal brain cancer, who were treated in FDA approved clinical trials with antineoplastons and who survived for over five years.

Recently, I attended the world neuro-oncology meeting in San Francisco where the lead study concluded that a placebo group of advanced brain tumor patients lived longer than patients undergoing the state-of-the-art cancer treatment. Right now, this is the best conventional medicine can offer these patients. We can and have to do better.

Based on survival data we reported to the FDA, I believe that our therapy is part of the answer for the over 100,000 Americans who are suffering from this type of cancer. Your two articles do not help advance the cure for this disease and will just funnel more people into ineffective treatment and death.

Stanislaw R. Burzynski, M.D., Ph.D.

Houston, TX